Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
NETRF’s 2023 Margie and Robert E Petersen Neuroendocrine Tumor Research Symposium brought together a hundred of the world’s foremost neuroendocrine cancer scientists in Boston. The
Almost half of patients diagnosed with pancreatic neuroendocrine tumors (PanNETs) have tumors that have spread to their liver, which correlates with poorer outcomes. Given this,
The Neuroendocrine Tumor Research Foundation celebrates a significant milestone in cancer therapy: a first-in-human CAR T cell therapy clinical trial for neuroendocrine tumors (NETs) will
Through her 2021 NETRF Investigator Award, Lisa Bodei, MD, PhD, professor of radiology at Weill Cornell Medical College, attending physician and director of targeted radionuclide
NETRF, in partnership with the North American Neuroendocrine Tumor Society (NANETS), is pleased to announce that Iacovos Michael, PhD, Scientist at Sunnybrook Research Institute and
NETRF-Funded Research Leads to Department of Defense Rare Cancers Research Program Grants
Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free
NETRF’s impact on neuroendocrine cancer research was evident at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference, held March 22-24 in Vienna. The ENETS
Peptide receptor radionuclide therapy, or PRRT, has been available as a treatment option for some forms of neuroendocrine tumors – particularly for those NETs expressing the somatostatin receptor-2 (SSTR2) protein.
Dr. Po Hien Ear’s research involves growing NET spheroid clusters in large enough numbers to be used to screen the potential anti-tumor properties of hundreds of therapeutic compounds.